Orforglipron's GI Safety Profile: A Meta-Analysis of GLP-1 Receptor Agonist Trials
The Gastrointestinal Safety of Orforglipron, a GLP-1 Receptor Agonist, in Adults With or Without Type 2 Diabetes: A Network Meta-Analysis of Randomized Controlled Trials.
Study Design
Population
N=a network meta-analysis of GLP-1 receptor agonist trials.
Intervention
Oral Orforglipron, with dose-dependent gastrointestinal side effects.
Outcome
Gastrointestinal safety profile, including pancreatitis and ALT levels.
Abstract
This network meta-analysis provides a robust and comprehensive safety profile for oral Orforglipron, confirming its dose-dependent gastrointestinal side effects, which are common with GLP-1 RAs. The findings are crucial for informing dosing strategies and patient counseling, suggesting that while GI issues are prevalent, the drug appears safe regarding pancreatitis and may offer beneficial effects on liver health by reducing ALT levels.
